J0896 HCPCS Level II code: Injection, luspatercept-aamt, 0.25 mg
J0896 is the HCPCS code for “Injection, luspatercept-aamt, 0.25 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0896Injection, luspatercept-aamt, 0.25 mg
Short description: Inj luspatercept-aamt 0.25mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0896 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jul 1, 2020
Where J0896 sits
- 1J codesDrugs administered other than orally
- 2Active code J0896Injection, luspatercept-aamt, 0.25 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0896 mean?
J0896 is the HCPCS code for “Injection, luspatercept-aamt, 0.25 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0896?
CMS lists J0896’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0896
All J codesJ0890Injection, peginesatide, 0.1 mg (for esrd on dialysis)J0891Injection, argatroban (accord), not therapeutically equivalent to j0883, 1 mg (for non-esrd use)J0892Injection, argatroban (accord), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis)J0893Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mgJ0894Injection, decitabine, 1 mgJ0895Injection, deferoxamine mesylate, 500 mgJ0897Injection, denosumab, 1 mgJ0898Injection, argatroban (auromedics), not therapeutically equivalent to j0883, 1 mg (for non-esrd use)J0899Injection, argatroban (auromedics), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis)J0900Injection, testosterone enanthate and estradiol valerate, up to 1 ccJ0901Vadadustat, oral, 1 mg (for esrd on dialysis)J0911Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)